Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing Safety, Tolerability and Long-term Efficacy of Bryostatin in the Treatment of Moderately Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
NCT04538066 is registered in ClinicalTrials.gov with Neurotrope Bioscience, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing Safety, Tolerability and Long-term Efficacy of Bryostatin in the Treatment of Moderately Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
- Lead sponsor
- Neurotrope Bioscience, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- August 30, 2020
- Completion date
- November 16, 2022
- Enrollment
- 122 (actual)
- Sites
- 19
Conditions
As the registry lists them; a condition with its own page is linked.